The stock of Tiziana Life Sciences Ltd (TLSA) has gone up by 17.35% for the week, with a -1.52% drop in the past month and a -12.38% drop in the past quarter. The volatility ratio for the week is 10.29%, and the volatility levels for the past 30 days are 9.58% for TLSA. The simple moving average for the past 20 days is 9.72% for TLSA’s stock, with a -17.77% simple moving average for the past 200 days.
Is It Worth Investing in Tiziana Life Sciences Ltd (NASDAQ: TLSA) Right Now?
The 36-month beta value for TLSA is at 0.77. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TLSA is 120.59M, and currently, shorts hold a 0.27% of that float. The average trading volume for TLSA on April 16, 2024 was 66.34K shares.
TLSA) stock’s latest price update
Tiziana Life Sciences Ltd (NASDAQ: TLSA)’s stock price has gone rise by 13.61 in comparison to its previous close of 0.44, however, the company has experienced a 17.35% increase in its stock price over the last five trading days. Proactive Investors reported 2024-04-11 that Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it will be presenting new data about its lead clinical asset foralumab at the Annual Meeting of the American Academy of Neurology being held from April 13 to 18 in Denver, Colorado. The company said the oral presentation, titled “Treatment of PIRA with Nasal Foralumab Dampens Microglial Activation and Stabilizes Clinical Progression in Non-Active Secondary Progressive MS,” will be part of the “Multiple Sclerosis: Therapeutics and Clinical Decision Making” session.
Analysts’ Opinion of TLSA
Many brokerage firms have already submitted their reports for TLSA stocks, with B. Riley Securities repeating the rating for TLSA by listing it as a “Buy.” The predicted price for TLSA in the upcoming period, according to B. Riley Securities is $8 based on the research report published on December 22, 2020 of the previous year 2020.
TLSA Trading at 2.57% from the 50-Day Moving Average
After a stumble in the market that brought TLSA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.11% of loss for the given period.
Volatility was left at 9.58%, however, over the last 30 days, the volatility rate increased by 10.29%, as shares surge +0.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.25% lower at present.
During the last 5 trading sessions, TLSA rose by +17.35%, which changed the moving average for the period of 200-days by -28.99% in comparison to the 20-day moving average, which settled at $0.4556. In addition, Tiziana Life Sciences Ltd saw -10.73% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for TLSA
The total capital return value is set at -0.74.
Based on Tiziana Life Sciences Ltd (TLSA), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -21.82. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -1434.29.
Currently, EBITDA for the company is -15.34 million with net debt to EBITDA at 0.62.
Conclusion
In conclusion, Tiziana Life Sciences Ltd (TLSA) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
